लोड हो रहा है...

A dose increased once-weekly bortezomib-based combination therapy for multiple myeloma

BACKGROUND: The purpose of the current study was to evaluate the efficacy and safety of a dose increased weekly Bortezomib (Bor) based combination therapy in multiple myeloma (MM) patients. RESULTS: The overall response rate (ORR) in the modified Bor group was 76.6%, composed of 40% complete respons...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Oncotarget
मुख्य लेखकों: Wei, Daolin, Tong, Yin, Bai, Haitao, Cai, Qi, Gao, Yanrong, Wang, Chun
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Impact Journals LLC 2016
विषय:
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC5342543/
https://ncbi.nlm.nih.gov/pubmed/27659525
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12162
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!